Drugs / MB0151
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06840821 | May 2025 → Jul 2028 expected | cancer | Mainline Biosciences (Shanghai) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB0151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06840821 ↗ |
| Route | Intravenous | “administered intravenously every 2 weeks” NCT06840821 ↗ |